ITM Isotopen Technologien München AG
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From ITM Isotopen Technologien München AG
Novartis is the leader when it comes to targeted cancer therapies incorporating radioisotopes. But plenty of companies are trying to break in to this market.
Lutathera yields a 72% reduction in the risk of progression or death in first-line GEP-NETs trial.
Plus deals involving Biocytogen, Neurocrine and Ona, Aeterna Zentaris/Ceapro, Teva/Biolojic Design, Pathos AI/Rain Oncology, Inhibitor Therapeutics/Johns Hopkins and more.
ITM is reaping benefits from long-term investment in radiopharmaceuticals manufacturing and is now looking to challenge its customer, Novartis, by bringing its first product to market.
- Medical Devices
- Radiopharmaceuticals, Contrast Agents
- Other Names / Subsidiaries
- ITG Isotope Technologies Garching GmbH
- ITM Solucin GmbH
- ITM Pharma Solutions GmbH
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.